이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

SomnoMed 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Amrita Blickstead

최고 경영자

AU$91.2k

총 보상

CEO 급여 비율	n/a
CEO 임기	4yrs
CEO 소유권	0.5%
경영진 평균 재임 기간	5yrs
이사회 평균 재임 기간	4yrs

최근 관리 업데이트

Recent updates

CEO

Amrita Blickstead

4yrs

테뉴어

AU$91,206

보상

Ms. Amrita Blickstead, MBA, BME, is Co-Chief Executive Officer and Executive Director of SomnoMed Limited. Ms. Blickstead was Non-Executive Director of SomnoMed Limited from August 24, 2020. Ms. Blickstead...

리더십 팀

이름	위치	테뉴어	보상	소유권
Amrita Blickstead	Co-CEO & Executive Director	no data	AU$91.21k	0.49% A$ 233.5k
Karen Borg	Co-CEO & Executive Director	no data	AU$91.21k	0.22% A$ 104.2k
Mark Harding	Vice President of Global Marketing	5.1yrs	AU$505.38k	0.067% A$ 31.6k
Matthew Conlon	Executive VP of Sales & Marketing - North America	4.8yrs	AU$623.78k	0.039% A$ 18.6k
Marco Van Kleef	Vice President of Marketing & Sales - Europe	no data	AU$525.51k	데이터 없음
Darren Collins	Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Terence Flitcroft	Company Secretary	29.6yrs	AU$10.56k	데이터 없음
Christopher Bedford	Vice President of Global Production and Product Development	no data	AU$159.55k	데이터 없음

5.0yrs

평균 재임 기간

경험이 풍부한 관리: RJV 의 관리팀은 경험 ( 4.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Amrita Blickstead	Co-CEO & Executive Director	4yrs	AU$91.21k	0.49% A$ 233.5k
Karen Borg	Co-CEO & Executive Director	3.8yrs	AU$91.21k	0.22% A$ 104.2k
Michael Gordon	Non-Executive Director	4yrs	AU$92.34k	0.10% A$ 49.2k
Iven Klineberg	Member of the Medical Advisory Board	no data	데이터 없음	데이터 없음
J. Gerschman	Member of the Medical Advisory Board	no data	데이터 없음	데이터 없음
Peter Cistulli	Chairman of the Medical Advisory Board	no data	데이터 없음	데이터 없음
Gaetano Russo	Chairman of the Board	4yrs	AU$184.68k	0.64% A$ 304.1k
Hamish Corlett	Non-Executive Director	6.3yrs	AU$91.21k	데이터 없음

4.0yrs

평균 재임 기간

경험이 풍부한 이사회: RJV 의 이사회는 경험(평균 재직 기간 3.8 년)으로 간주됩니다.

SomnoMed 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

No independent directors

SomnoMed Limited, Annual General Meeting, Nov 24, 2023

SomnoMed Limited Announces Resignation of Hilton Brett as Non-Executive Director

Somnomed Limited Announces Executive Changes

No independent directors

SomnoMed Limited, Annual General Meeting, Nov 25, 2022

Recent updates

New major risk - Shareholder dilution

No independent directors

SomnoMed Limited has filed a Follow-on Equity Offering in the amount of AUD 22.6 million.

New major risk - Share price stability

SomnoMed Limited to Report First Half, 2024 Results on Feb 28, 2024

New major risk - Revenue and earnings growth

SomnoMed Limited, Annual General Meeting, Nov 24, 2023

SomnoMed Limited Announces Resignation of Hilton Brett as Non-Executive Director

Full year 2023 earnings released: AU$0.10 loss per share (vs AU$0.056 loss in FY 2022)

SomnoMed Limited has completed a Follow-on Equity Offering in the amount of AUD 15.499249 million.

SomnoMed Limited has completed a Follow-on Equity Offering in the amount of AUD 15.498845 million.

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Full year 2023 earnings released: AU$0.10 loss per share (vs AU$0.056 loss in FY 2022)

New minor risk - Financial data availability

New minor risk - Share price stability

SomnoMed Limited to Report Q4, 2023 Results on Aug 24, 2023

Somnomed Limited Announces Executive Changes

First half 2023 earnings released: AU$0.047 loss per share (vs AU$0.038 loss in 1H 2022)

No independent directors

SomnoMed Limited, Annual General Meeting, Nov 25, 2022

Full year 2022 earnings released: AU$0.056 loss per share (vs AU$0.014 loss in FY 2021)

SomnoMed Limited Provides Earnings Guidance for the Year 2023

No independent directors

Global CEO recently sold €54k worth of stock

First half 2022 earnings: EPS in line with expectations, revenues disappoint

SomnoMed Introduces Rest Assure

SomnoMed Introduces Rest Assure

SomnoMed Limited to Report First Half, 2022 Results on Feb 22, 2022

SomnoMed Limited Announces World First Technology Enabled Oral Appliance

Chairman of the Board recently bought €315k worth of stock

Full year 2021 earnings released: AU$0.014 loss per share (vs AU$0.007 loss in FY 2020)

Non-Executive Director recently bought €50k worth of stock

Full year 2021 earnings released: AU$1.38 loss per share (vs AU$0.007 loss in FY 2020)

Forecast to breakeven in 2023

Non-Executive Director recently bought €51k worth of stock

New 90-day low: €1.15

First half 2021 earnings released: EPS AU$0.008 (vs AU$0.014 in 1H 2020)

Somnomed Limited Appoints Karen Borg to Board of Directors, Effective November 26, 2020

Full year earnings released - €0.0069 loss per share

New 90-day high: €1.28

New 90-day high - €0.94

Chairman of the Board recently bought €126k worth of stock

Earnings released

SomnoMed Limited to Report Fiscal Year 2020 Results on Aug 24, 2020

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간